TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 387001

Group type: EXPERIMENTAL
Intervention: Luteinizing hormone-releasing hormone (LRH, 500 micrograms, intramuscularly injected)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 6
Study: 29991338

Group type: EXPERIMENTAL
Intervention: Same-gender IPCM with physical violence
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: Same-gender IPCM without physical violence
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: Different-gender IPCM with physical violence
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: Different-gender IPCM without physical violence
Number of subjects: 738
Study: 30986809

Group type: EXPERIMENTAL
Intervention: CDK4/6 inhibitors (palbociclib or ribociclib) in combination with cetuximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of palbociclib/cetuximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CDK4/6 inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapies (CDK4/6 inhibitors with other agents)
Number of subjects: 0
Study: 25265991

Group type: EXPERIMENTAL
Intervention: Motivational interviewing via telephone calls (average duration 9.5 minutes, conducted fortnightly)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Motivational interviewing with interpreter services
Number of subjects: 26
Study: 23792937

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 1000 IU/day
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Ergocalciferol 1000 IU/day
Number of subjects: 95

Group type: COMPARATOR
Intervention: Cholecalciferol and Ergocalciferol (both treatments)
Number of subjects: 95
Study: 21035237

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg submucosally
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg intramuscularly
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no steroid)
Number of subjects: 30
Study: 20112595

Group type: EXPERIMENTAL
Intervention: Clarithromycin (CM)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 17556681

Group type: EXPERIMENTAL
Intervention: RF+FV group (reduced fat intake and increased intake of water-rich foods)
Number of subjects: 97

Group type: COMPARATOR
Intervention: RF group (reduced fat intake)
Number of subjects: 97
Study: 15135483

Group type: EXPERIMENTAL
Intervention: G17DT 10 microg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: G17DT 100 microg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: G17DT 250 microg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: G17DT 250 microg (stage IV)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: G17DT
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: G17DT antibodies
Number of subjects: 52
Study: 11466984

Group type: EXPERIMENTAL
Intervention: Presumed non-effective reflexological treatment (Group A)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Presumed effective reflexological treatment (Group B)
Number of subjects: 63

Group type: COMPARATOR
Intervention: No treatment - only observation (Group C)
Number of subjects: 63
Study: 9728931

Group type: EXPERIMENTAL
Intervention: LPONL(G)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LPONL(A)
Number of subjects: 0
Study: 7991126

Group type: EXPERIMENTAL
Intervention: MN BR test with electrical stimulation of the mental nerve
Number of subjects: 28
Study: 2600755

Group type: EXPERIMENTAL
Intervention: Counter-rotary toothbrush
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional toothbrush
Number of subjects: 24
Study: 4448876

Group type: EXPERIMENTAL
Intervention: Modeling treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Viewing the operatory and professional staff
Number of subjects: 15
Study: 30199900

Group type: EXPERIMENTAL
Intervention: Side-viewing endoscopy
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Cap-assisted endoscopy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 62
Study: 28371897

Group type: EXPERIMENTAL
Intervention: Targeted screening for at-risk alcohol use
Number of subjects: 3562

Group type: COMPARATOR
Intervention: Universal screening for at-risk alcohol use
Number of subjects: 3562
Study: 25887238

Group type: EXPERIMENTAL
Intervention: Multifaceted educational program for nursing home care staff on assessment and treatment of fecal incontinence
Number of subjects: 240

Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 240
Study: 23190342

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (20 U per cycle, up to eight treatment cycles, treatment interval at least 85 days)
Number of subjects: 796
Study: 22191131

Group type: EXPERIMENTAL
Intervention: Vacuum Assisted Closure (VAC) therapy
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard wound care
Number of subjects: 67
Study: 19656069

Group type: EXPERIMENTAL
Intervention: Mefloquine (MQ) 15 mg/kg in a single intake twice during pregnancy
Number of subjects: 1601

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP) 1500 mg sulfadoxine and 75 mg pyrimethamine in a single intake twice during pregnancy
Number of subjects: 1601

Group type: EXPERIMENTAL
Intervention: Mefloquine (MQ)
Number of subjects: 1601

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 1601
Study: 17985403

Group type: EXPERIMENTAL
Intervention: Sildenafil 20 mg
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Sildenafil 40 mg
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Sildenafil 80 mg
Number of subjects: 278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study: 12920042

Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP) infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Physiologic saline infusion (placebo)
Number of subjects: 10
Study: 10839552

Group type: EXPERIMENTAL
Intervention: Antibiotics (dosage and duration not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drugs, alpha-blocking agents, anticholinergic agents or other therapies
Number of subjects: 0
Study: 9099447

Group type: EXPERIMENTAL
Intervention: Partial-area method (5h AUC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Symmetrical confidence intervals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-point short-term AUC
Number of subjects: 0
Study: 8404314

Group type: EXPERIMENTAL
Intervention: diltiazem SR
Number of subjects: 168

Group type: COMPARATOR
Intervention: diltiazem HCL
Number of subjects: 168
Study: 3533264

Group type: EXPERIMENTAL
Intervention: Captopril 150 mg daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: Methyldopa 750 mg daily
Number of subjects: 41
Study: 28580810

Group type: EXPERIMENTAL
Intervention: Youth Empowerment Solutions (YES) program
Number of subjects: 367
Study: 27013473

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Sham electro-acupuncture (SEA)
Number of subjects: 63
Study: 25038985

Group type: EXPERIMENTAL
Intervention: High-frequency deep TMS treatment
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Low-frequency deep TMS treatment
Number of subjects: 115

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 115
Study: 22858177

Group type: EXPERIMENTAL
Intervention: Revaprazan 200 mg once daily for 7 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Itopride 50 mg TID for 7 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of revaprazan and itopride
Number of subjects: 30
Study: 20133068

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (500 μg of sodium selenite during RT and 300 μg on non-RT days)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (no selenium supplementation)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (SG)
Number of subjects: 81
Study: 18603821

Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg/day
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 17
Study: 15749950

Group type: EXPERIMENTAL
Intervention: Dental screening program (study group)
Number of subjects: 4500

Group type: COMPARATOR
Intervention: No dental screening program (control group)
Number of subjects: 4500
Study: 12623814

Group type: EXPERIMENTAL
Intervention: 130 degrees short arc length intrastromal corneal ring segments (ICRS) with thicknesses ranging from 0.25 to 0.50 mm by 0.05 mm increments
Number of subjects: 10
Study: 10368794

Group type: EXPERIMENTAL
Intervention: Oral DHEAS (50 mg/day)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Oral DHEAS (50 mg/day) + transdermal estradiol (50 micrograms/patch)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Transdermal estradiol (50 micrograms/day)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Groups treated with estradiol alone or plus DHEAS
Number of subjects: 22
Study: 8904583

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 1877335

Group type: EXPERIMENTAL
Intervention: Regular hydrotherapy for 31/2 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: No treatment (control) for 31/2 weeks
Number of subjects: 61
Study: 7174915

Group type: EXPERIMENTAL
Intervention: Topical 8‐methoxypsoralen (8‐MOP) 0.1%
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Topical 8‐methoxypsoralen (8‐MOP) 0.5%
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Topical 8‐methoxypsoralen (8‐MOP) 1%
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Topical 8‐methoxypsoralen (8‐MOP)
Number of subjects: 73
Study: 31102024

Group type: EXPERIMENTAL
Intervention: T-DM1
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: T-DM1 plus pertuzumab
Number of subjects: 375
Study: 29604316

Group type: EXPERIMENTAL
Intervention: 0.425% phytate/F toothpaste
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.85% phytate/F toothpaste
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.85% phytate/Zn/F toothpaste
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: F-only toothpaste (1150 ppm NaF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zn/F toothpaste (0.3% ZnCl2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0% F placebo toothpaste
Number of subjects: 0
Study: 26914406

Group type: EXPERIMENTAL
Intervention: Brodalumab 140 mg
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg
Number of subjects: 661

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 661
Study: 25431880

Group type: EXPERIMENTAL
Intervention: Fish (Atlantic salmon three times per week from September to February)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control (alternative meal, e.g., chicken, pork, or beef three times per week during the same period)
Number of subjects: 95
Study: 22260297

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine 1.5 mg/kg followed by a continuous infusion of 2 mg/kg/h
Number of subjects: 52

Group type: COMPARATOR
Intervention: Physiological saline (control)
Number of subjects: 52
Study: 19801174

Group type: COMPARATOR
Intervention: Control arm (no screening)
Number of subjects: 15822
Study: 17352868

Group type: EXPERIMENTAL
Intervention: Chaige Qingre Granule (6 g, 4 times daily for 3 days)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Fufang Shuanghua Granule (6 g, 4 times daily for 3 days)
Number of subjects: 172
Study: 15655204

Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication with simple sutured crural closure (n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Laparoscopic Nissen fundoplication with prosthetic hiatal closure (n = 50)
Number of subjects: 100
Study: 12885350

Group type: EXPERIMENTAL
Intervention: Vaccination with 10(7) or 10(8) irradiated CD80-modified tumor cells with GM-CSF or BCG, three times at 2-week intervals and then monthly until progressive disease developed.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vaccination with 10(8) tumor cell dose.
Number of subjects: 30
Study: 10534821

Group type: EXPERIMENTAL
Intervention: Teledermatology consultation
Number of subjects: 197

Group type: COMPARATOR
Intervention: Hospital consultation
Number of subjects: 197
Study: 9346678

Group type: EXPERIMENTAL
Intervention: ganciclovir (6 mg/kg/day intravenously for a total of 100 days)
Number of subjects: 26

Group type: COMPARATOR
Intervention: acyclovir (10 mg/kg every 8 hours intravenously until discharged and then 800 mg orally every 6 hours for a total of 100 days)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: ganciclovir
Number of subjects: 26

Group type: COMPARATOR
Intervention: acyclovir
Number of subjects: 26
Study: 1768538

Group type: EXPERIMENTAL
Intervention: 2% lignocaine with adrenaline 1:200,000
Number of subjects: 20

Group type: COMPARATOR
Intervention: 2% lignocaine
Number of subjects: 20
Study: 7150406

Group type: EXPERIMENTAL
Intervention: Supervised bicycle ergometer exercise for 2 months followed by 2 months of unsupervised training
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Supervised bicycle ergometer exercise
Number of subjects: 59
Study: 30382352

Group type: EXPERIMENTAL
Intervention: Remotiv 250 (250 mg of H. perforatum)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Remotiv 500 (500 mg of H. perforatum)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 28217975

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 26358764

Group type: COMPARATOR
Intervention: Topical combination of calcipotriol and betamethasone (Group A)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Monochromatic excimer light (MEL) (Group B)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 44
Study: 24138555

Group type: EXPERIMENTAL
Intervention: Non-HD day with one meal served at baseline (NHDM1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: HD day with one meal served during HD (HDM1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: HD day with two meals served during and after HD (HDM2)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy controls (session 1)
Number of subjects: 12
Study: 22946500

Group type: EXPERIMENTAL
Intervention: DCR with both anterior and posterior flap anastomosis (Group 1)
Number of subjects: 164

Group type: COMPARATOR
Intervention: DCR with only anterior flap anastomosis (Group 2)
Number of subjects: 164
Study: 18574489

Group type: EXPERIMENTAL
Intervention: Regular passive movements administered for 10 min, 10 times a week for 6 months.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (untreated ankles).
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Experimental group (passive movements).
Number of subjects: 20
Study: 17959531

Group type: EXPERIMENTAL
Intervention: Diffusion tensor magnetic resonance imaging (DTI)
Number of subjects: 45
Study: 10768528

Group type: EXPERIMENTAL
Intervention: Task-related circuit training (experimental group)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Upper-limb tasks (control group)
Number of subjects: 12
Study: 8633581

Group type: EXPERIMENTAL
Intervention: Chloroquine (500 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sulfasalazine (3 g/day)
Number of subjects: 40
Study: 1480364

Group type: EXPERIMENTAL
Intervention: Retrobulbar anesthesia (LA)
Number of subjects: 95

Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 95
Study: 3881558

Group type: EXPERIMENTAL
Intervention: Clonidine treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gradual methadone reduction
Number of subjects: 0
Study: 30412655

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg or 25 mg
Number of subjects: 1517
Study: 29326330

Group type: EXPERIMENTAL
Intervention: Multi-component intervention including individualised care/action plans and telephone consults (12-weekly then 9-monthly)
Number of subjects: 470

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 470
Study: 27279511

Group type: EXPERIMENTAL
Intervention: TAP block using 20 mL 0.25% bupivacaine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control block using 20 mL 0.9% Sodium chloride
Number of subjects: 34
Study: 24667487

Group type: EXPERIMENTAL
Intervention: levomilnacipran extended-release (ER)
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 22964983

Group type: EXPERIMENTAL
Intervention: Maoto+oseltamivir (group 3)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Zanamivir (group 4)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Maoto (group 1)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control (oseltamivir, group 2)
Number of subjects: 150
Study: 19578163

Group type: EXPERIMENTAL
Intervention: Pravastatin therapy (40 mg/day)
Number of subjects: 480
Study: 18062391

Group type: EXPERIMENTAL
Intervention: Customized Purell Instant Hand Sanitizer regimen, education, reinforcement
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Customized Purell Instant Hand Sanitizer regimen
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2
Study: 16173357

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trauma Model Therapy
Number of subjects: 0
Study: 12666888

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 15% carbamide peroxide
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 20% carbamide peroxide
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 10%, 15%, and 20% carbamide peroxide
Number of subjects: 59
Study: 9885787

Group type: EXPERIMENTAL
Intervention: CCK-4 injection during the follicular phase
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: CCK-4 injection during the luteal phase
Number of subjects: 39

Group type: COMPARATOR
Intervention: CCK-4 injection (both phases)
Number of subjects: 39
Study: 7726308

Group type: EXPERIMENTAL
Intervention: Lactate infusion with 0.9% sodium chloride
Number of subjects: 34

Group type: COMPARATOR
Intervention: Lactate infusion with 5% dextrose in water
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both infusions
Number of subjects: 34
Study: 2174121

Group type: EXPERIMENTAL
Intervention: MK-571 (160 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30992301

Group type: EXPERIMENTAL
Intervention: Ixazomib in combination with MEC (mitoxantrone, etoposide, cytarabine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MEC (mitoxantrone, etoposide, cytarabine) alone
Number of subjects: 0
Study: 28033159

Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mL of 0.4% dexamethasone)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (1 mL of saline)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 25450293

Group type: EXPERIMENTAL
Intervention: Leptin treatment in cultured endometrial cells (Ishikawa cells)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High serum leptin levels in overweight/obese PCOS patients
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (12 control women)
Number of subjects: 12
Study: 23932008

Group type: EXPERIMENTAL
Intervention: Casual or unexpected partners
Number of subjects: 1469

Group type: EXPERIMENTAL
Intervention: Partners drinking alcohol 2 hours prior to sex
Number of subjects: 1469

Group type: EXPERIMENTAL
Intervention: >=3 years age discordant partners
Number of subjects: 1469

Group type: EXPERIMENTAL
Intervention: Partners met in public places
Number of subjects: 1469
Study: 22263401

Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 30
Study: 19923847

Group type: EXPERIMENTAL
Intervention: Extended-interval dosing (triptorelin 3.75 mg by intramuscular injection every 6 weeks for a total of 4 doses)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional dosing (1 injection every 4 weeks for a total of 6 doses)
Number of subjects: 70
Study: 17427818

Group type: EXPERIMENTAL
Intervention: Self-etching, self-priming dentin bonding agent
Number of subjects: 76

Group type: COMPARATOR
Intervention: Self-priming resin requiring a separate etch step
Number of subjects: 76
Study: 16163749

Group type: EXPERIMENTAL
Intervention: Paroxetine and Nortriptyline
Number of subjects: 248

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 248
Study: 11967670

Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic surgery (HALS)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional laparoscopic surgery (LS)
Number of subjects: 54
Study: 9475525

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: No photodynamic therapy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 48
Study: 7620004

Group type: EXPERIMENTAL
Intervention: Piperacillin (4 g) three times daily for up to 7 days
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo three times daily for up to 7 days
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 2244441

Group type: EXPERIMENTAL
Intervention: Bupivacaine-epinephrine mixture (0.5% bupivacaine, 5 micrograms/ml epinephrine)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Plain bupivacaine
Number of subjects: 32
Study: 420388

Group type: EXPERIMENTAL
Intervention: Mobile cast brace
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard cylinder cast
Number of subjects: 16
Study: 31332549

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation plus routine antihistamine medication (cetirizine)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cetirizine plus placebo
Number of subjects: 80
Study: 29258261

Group type: EXPERIMENTAL
Intervention: Oligofructose (Orafti® P95) at 15 g/day
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Oligofructose (Orafti® P95) at 10 g/day
Number of subjects: 97

Group type: COMPARATOR
Intervention: Maltodextrin (placebo)
Number of subjects: 97
Study: 25421343

Group type: EXPERIMENTAL
Intervention: Proprioceptive training (15-min circle training, 5 times per week for 12 weeks)
Number of subjects: 28
Study: 22858513

Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 96

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 96
Study: 21715514

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (2000 IU once daily)
Number of subjects: 92